SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-016067
Filing Date
2023-05-10
Accepted
2023-05-10 08:30:11
Documents
14
Period of Report
2023-05-10
Items
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51781
2 ex99-1.htm EX-99.1 14967
3 ex99-2.htm EX-99.2 14703
  Complete submission text file 0001493152-23-016067.txt   263773

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE mrzm-20230510.xsd EX-101.SCH 3227
5 XBRL LABEL FILE mrzm-20230510_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE mrzm-20230510_pre.xml EX-101.PRE 22359
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3382
Mailing Address 555 HERITAGE DRIVE SUITE 205 JUPITER FL 33458
Business Address 555 HERITAGE DRIVE SUITE 205 JUPITER FL 33458 561-935-9955
MARIZYME INC (Filer) CIK: 0001413754 (see all company filings)

IRS No.: 825464863 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-53223 | Film No.: 23904464
SIC: 2834 Pharmaceutical Preparations